About INmune Bio, Inc.
https://www.inmunebio.comINmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
CEO
Raymond Joseph Tesi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 38
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:1.19M
Value:$1.83M
VANGUARD GROUP INC
Shares:876.29K
Value:$1.35M
BLACKROCK INC.
Shares:812.89K
Value:$1.25M
Summary
Showing Top 3 of 83
About INmune Bio, Inc.
https://www.inmunebio.comINmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.41M ▼ | $-6.47M ▲ | 0% | $-0.24 ▲ | $-6.44M ▲ |
| Q2-2025 | $0 ▼ | $24.57M ▲ | $-24.46M ▼ | 0% ▲ | $-1.05 ▼ | $-8.06M ▲ |
| Q1-2025 | $50K ▲ | $9.96M ▲ | $-9.74M ▼ | -19.48K% ▼ | $-0.43 ▼ | $-9.9M ▼ |
| Q4-2024 | $0 | $9.47M ▼ | $-9.22M ▲ | 0% | $-0.41 ▲ | $-9.22M ▲ |
| Q3-2024 | $0 | $12.29M | $-12.09M | 0% | $-0.6 | $-12.09M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $27.73M ▼ | $33.36M ▼ | $7.98M ▼ | $25.38M ▼ |
| Q2-2025 | $33.37M ▲ | $37.68M ▼ | $8.82M ▲ | $28.87M ▼ |
| Q1-2025 | $19.34M ▼ | $37.8M ▼ | $8.13M ▲ | $29.67M ▼ |
| Q4-2024 | $20.92M ▼ | $39.56M ▼ | $7.46M ▼ | $32.1M ▼ |
| Q3-2024 | $33.55M | $52.78M | $14.11M | $38.67M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-6.47M ▲ | $-5.44M ▲ | $-193K ▲ | $0 ▼ | $-5.64M ▼ | $-5.63M ▲ |
| Q2-2025 | $-24.46M ▼ | $-7.38M ▼ | $-706K ▼ | $22.27M ▲ | $14.04M ▲ | $-8.08M ▼ |
| Q1-2025 | $-9.74M ▼ | $-6.82M ▲ | $0 | $5.27M ▲ | $-1.58M ▲ | $-6.82M ▲ |
| Q4-2024 | $-9.22M ▲ | $-11.01M ▼ | $0 | $-2.08M ▼ | $-12.63M ▼ | $-11.01M ▼ |
| Q3-2024 | $-12.09M | $-6.99M | $0 | $9.79M | $2.48M | $-6.99M |
CEO
Raymond Joseph Tesi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 38
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:1.19M
Value:$1.83M
VANGUARD GROUP INC
Shares:876.29K
Value:$1.35M
BLACKROCK INC.
Shares:812.89K
Value:$1.25M
Summary
Showing Top 3 of 83